Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

PURPOSE: This phase I b study evaluated the safety and anti-tumor activity of pembrolizumab in Japanese patients with advanced melanoma. METHODS: Pembrolizumab (2 mg/kg) was given every 3 weeks (Q3W) for up to 2 years or until confirmed progression or unacceptable toxicity. The tumor response was as...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Yamazaki, Naoya, Takenouchi, Tatsuya, Fujimoto, Manabu, Ihn, Hironobu, Uchi, Hiroshi, Inozume, Takashi, Kiyohara, Yoshio, Uhara, Hisashi, Nakagawa, Kazuhiko, Furukawa, Hiroshi, Wada, Hidefumi, Noguchi, Kazuo, Shimamoto, Takashi, Yokota, Kenji
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5364262/
https://ncbi.nlm.nih.gov/pubmed/28283736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3237-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars